{"disease":{"id":"fibrosis-lung","name":"fibrosis lung"},"drugs":{"marketed":[{"drug_id":"acetadote","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetadote","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"acetylcysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetadote","generic_name":"Acetylcysteine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glutathione levels; reactive metabolite of acetaminophen","drug_class":"Antidote","quality_score":62,"revenue":null,"mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate."},{"drug_id":"acetylcystein","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetylcystein","company_name":"University Hospital, Strasbourg, France","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tezacaftor","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symdeko (Copackaged)","generic_name":"TEZACAFTOR","company_name":"Vertex Pharms","drug_phase":"marketed","molecular_target":"CFTR","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Tezacaftor and ivacaftor work together to increase the amount and function of CFTR protein at the cell surface, enhancing chloride transport."},{"drug_id":"adenosine-phosphate","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenovite","generic_name":"ADENOSINE PHOSPHATE","company_name":"","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Adenosine Receptor Agonist","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ivacaftor","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kalydeco","generic_name":"IVACAFTOR","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"Cystic fibrosis transmembrane conductance regulator","drug_class":"Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]","quality_score":10,"revenue":null,"mechanism":"Kalydeco works by helping the defective protein in cystic fibrosis cells function more normally."},{"drug_id":"cysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cysteine Hydrochloride","generic_name":"CYSTEINE","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Vitamin C [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Fibrosis of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"kalydeco","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Kalydeco","company_name":"Concert Pharmaceuticals","drug_phase":"marketed","molecular_target":"Cystic fibrosis transmembrane conductance regulator","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Fibrosis of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05253859","title":"CFTR Modulators and Gastrointestinal Complications","phase":"","overall_status":"COMPLETED","enrollment_count":47023,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT05681962","title":"Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Magna Graecia","has_results":false},{"nct_id":"NCT05382572","title":"Pulmonary Fibrosis Foundation Community Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT06106789","title":"A Study of the Clinical Benefit of Tobramycin Inhalation Solution","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT03120481","title":"Controls for Respiratory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1572,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03995654","title":"Research of Burden of Interstititial Lung Diseases in Turkey","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Karadeniz Technical University","has_results":false},{"nct_id":"NCT05538299","title":"Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials","phase":"","overall_status":"UNKNOWN","enrollment_count":995,"lead_sponsor_name":"Samuel Hatfield","has_results":false},{"nct_id":"NCT04016168","title":"Idiopathic Pulmonary Fibrosis and Serum Bank","phase":"","overall_status":"COMPLETED","enrollment_count":903,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT04016181","title":"The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT04760548","title":"Segmentation of Structural Abnormalities in Chronic Lung Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Hôpital Haut Lévêque","has_results":false},{"nct_id":"NCT06457269","title":"Evaluating the Potential of Large Language Models for Respiratory Disease Consultations","phase":"NA","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"North Sichuan Medical College","has_results":false},{"nct_id":"NCT04171583","title":"Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways","phase":"","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"University Hospital Muenster","has_results":false},{"nct_id":"NCT04708782","title":"Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"United Therapeutics","has_results":false},{"nct_id":"NCT05255991","title":"Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":597,"lead_sponsor_name":"United Therapeutics","has_results":false},{"nct_id":"NCT03747627","title":"BPF Genetics of ILD Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"University of Dundee","has_results":false},{"nct_id":"NCT06751069","title":"Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06644144","title":"P4O2 ILD Extension","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT06383819","title":"Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":392,"lead_sponsor_name":"NPO Petrovax","has_results":false},{"nct_id":"NCT05251467","title":"A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT02713347","title":"Advancing Symptom Alleviation With Palliative Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05785624","title":"A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":286,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT04624490","title":"Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Mario Castro, MD, MPH","has_results":false},{"nct_id":"NCT06883448","title":"Implementation of Home Monitoring in Patients With Pulmonary Fibrosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT07396467","title":"Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03261037","title":"A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period","phase":"NA","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07269262","title":"SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers","phase":"NA","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT02036970","title":"Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06416163","title":"FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT07486206","title":"Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"Hospital de Granollers","has_results":false},{"nct_id":"NCT07345052","title":"Western Sweden Systemic Sclerosis Project","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT05784207","title":"An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors","phase":"","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT03142191","title":"A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":138,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT00677560","title":"The Natural History of Small Airways Physiology in Diseased and Healthy States","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT04619680","title":"The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT05752019","title":"TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03535545","title":"Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07482917","title":"Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"Hospital de Granollers","has_results":false},{"nct_id":"NCT02888730","title":"Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":86,"lead_sponsor_name":"Virginie ESCABASSE","has_results":false},{"nct_id":"NCT07201922","title":"A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03843723","title":"Cystic Fibrosis and Fit-to-Fly","phase":"","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06482190","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Shenzhen Resproly Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06189820","title":"Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Erasme University Hospital","has_results":false},{"nct_id":"NCT04527354","title":"Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"PHARMENTERPRISES LLC","has_results":false},{"nct_id":"NCT03753828","title":"Estimated Impact of Fungal Colonization in Cystic Fibrosis From Secondary Exploitation of MucoFong Database.","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06636487","title":"Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Copenhagen University Hospital, Hvidovre","has_results":false},{"nct_id":"NCT05616221","title":"Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Armata Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06413459","title":"Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Ospedale San Raffaele","has_results":false},{"nct_id":"NCT06188988","title":"Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT06325696","title":"H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}